Cargando…
Hepatic perivascular epithelioid cell tumor: A case report
BACKGROUND: Perivascular epithelioid cell tumor (PEComa) is a mesenchymal tumor with histologic and immunophenotypic characteristics of perivascular epithelioid cells, has a low incidence, and can involve multiple organs. PEComa originating in the liver is extremely rare, with most cases being benig...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131209/ https://www.ncbi.nlm.nih.gov/pubmed/35665123 http://dx.doi.org/10.12998/wjcc.v10.i13.4273 |
_version_ | 1784713136139403264 |
---|---|
author | Li, Yong-Fang Wang, Liang Xie, Yi-Jing |
author_facet | Li, Yong-Fang Wang, Liang Xie, Yi-Jing |
author_sort | Li, Yong-Fang |
collection | PubMed |
description | BACKGROUND: Perivascular epithelioid cell tumor (PEComa) is a mesenchymal tumor with histologic and immunophenotypic characteristics of perivascular epithelioid cells, has a low incidence, and can involve multiple organs. PEComa originating in the liver is extremely rare, with most cases being benign, and only a few cases are malignant. Good outcomes are achieved with radical surgical resection, but there is no effective treatment for some large tumors and specific locations that are contraindicated for surgery. CASE SUMMARY: A 32-year-old woman was admitted to our hospital with a palpable abdominal mass and progressive deterioration since the previous month. An ultrasound-guided percutaneous liver aspiration biopsy was performed. Postoperative pathological immunohistochemical staining was HMB45, Melan-A, and smooth muscle actin positive. Perivascular epithelioid tumor was diagnosed. The tumor was large and could not be completely resected by surgery. Further digital subtraction angiography revealed a rich tumor blood supply, and interventional embolization followed by surgery was recommended. Finally, the patient underwent transarterial embolization (TAE) combined with sorafenib for four cycles. Angiography reexamination indicated no clear vascular staining of the tumor, and the tumor had shrunk. The patient was followed up for a short period of time, achieved a stable condition, and surgery was recommended. CONCLUSION: Adjuvant combination treatment with TAE and sorafenib is safe and feasible as it shrinks the tumor preoperatively and facilitates surgery. |
format | Online Article Text |
id | pubmed-9131209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-91312092022-06-04 Hepatic perivascular epithelioid cell tumor: A case report Li, Yong-Fang Wang, Liang Xie, Yi-Jing World J Clin Cases Case Report BACKGROUND: Perivascular epithelioid cell tumor (PEComa) is a mesenchymal tumor with histologic and immunophenotypic characteristics of perivascular epithelioid cells, has a low incidence, and can involve multiple organs. PEComa originating in the liver is extremely rare, with most cases being benign, and only a few cases are malignant. Good outcomes are achieved with radical surgical resection, but there is no effective treatment for some large tumors and specific locations that are contraindicated for surgery. CASE SUMMARY: A 32-year-old woman was admitted to our hospital with a palpable abdominal mass and progressive deterioration since the previous month. An ultrasound-guided percutaneous liver aspiration biopsy was performed. Postoperative pathological immunohistochemical staining was HMB45, Melan-A, and smooth muscle actin positive. Perivascular epithelioid tumor was diagnosed. The tumor was large and could not be completely resected by surgery. Further digital subtraction angiography revealed a rich tumor blood supply, and interventional embolization followed by surgery was recommended. Finally, the patient underwent transarterial embolization (TAE) combined with sorafenib for four cycles. Angiography reexamination indicated no clear vascular staining of the tumor, and the tumor had shrunk. The patient was followed up for a short period of time, achieved a stable condition, and surgery was recommended. CONCLUSION: Adjuvant combination treatment with TAE and sorafenib is safe and feasible as it shrinks the tumor preoperatively and facilitates surgery. Baishideng Publishing Group Inc 2022-05-06 2022-05-06 /pmc/articles/PMC9131209/ /pubmed/35665123 http://dx.doi.org/10.12998/wjcc.v10.i13.4273 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Case Report Li, Yong-Fang Wang, Liang Xie, Yi-Jing Hepatic perivascular epithelioid cell tumor: A case report |
title | Hepatic perivascular epithelioid cell tumor: A case report |
title_full | Hepatic perivascular epithelioid cell tumor: A case report |
title_fullStr | Hepatic perivascular epithelioid cell tumor: A case report |
title_full_unstemmed | Hepatic perivascular epithelioid cell tumor: A case report |
title_short | Hepatic perivascular epithelioid cell tumor: A case report |
title_sort | hepatic perivascular epithelioid cell tumor: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131209/ https://www.ncbi.nlm.nih.gov/pubmed/35665123 http://dx.doi.org/10.12998/wjcc.v10.i13.4273 |
work_keys_str_mv | AT liyongfang hepaticperivascularepithelioidcelltumoracasereport AT wangliang hepaticperivascularepithelioidcelltumoracasereport AT xieyijing hepaticperivascularepithelioidcelltumoracasereport |